GPX Medical publicerade idag den 15 februari sin bokslutskommuniké för år 2021.
Redeye comments on Medivir's Q4 report.
Redeye leaves its comment on Respiratorius following the year-end report.
Calliditas lead project in the clinical pipeline besides Nefecon/TARPEYO is Setanaxib targeting prim...
Ascelia Pharma har kommunicerat förändringar i SPARKLE-studien där två nya grupper läggs till i prot...
Freja eID's strong commercial momentum through 2021 laid a promising foundation to fuel its financia...
Exel’s Q4 results extended recent earnings reports trends to a certain degree.
Solteq reports Q4 results on February 17th. We foresee some continued softness due to the current en...
Marimekko’s Q4 result outpaced our estimates and the company grew very strongly.
Probi redovisade ett kvartal präglat av framgångar i Europa och Asien medan utmaningarna i region Am...
Redeye lowers its fair value range on the back of Bambuser's year-end report.
Redeye argues that the lower-than-anticipated sales do not reflect the long-term case of Episurf and...
Redeye updates its estimates following last week's Q4 report, where sales grew double-digit, and pro...
Redeye is cautiously optimistic to yesterday’s licensing agreement between Nexstim and Magnus Medica...
Redeye states that the Q4 report was weaker than expected, especially regarding projects being delay...
Redeye comments on GiG’s Q4-results where topline came in stronger than expected while EBITDA was so...
Med en nyligen presenterad Q4-rapport anser vi att ChromoGenics fortsätter röra sig i rätt riktning ...
Kollect on Demand publicerade idag den 14 februari 2021 sin delårsrapport för fjärde kvartalet 2021.
Vaisala reports its Q4 result on Friday. In Q4, we expect revenue growth to scale till bottom rows a...
Stark lönsamhet och trading update Omsättningen i Q4 uppgick till EUR 98,2m vilket var i linje med v...
